Advertisement

Future Research

  • Konstantinos Dimopoulos
  • Alessia David
Chapter
Part of the Congenital Heart Disease in Adolescents and Adults book series (CHDAA)

Abstract

As heart failure is becoming ever more common in congenital heart disease (CHD), there is increasing need for studies to support clinical practice. Indeed, most practice in CHD is based on soft evidence from cohort studies and expert consensus, resulting in significant variation. This chapter provides an overview of the areas of need and potential future research in congenital heart disease and heart failure.

Keywords

Research Risk stratification Therapy Prevention Genetics 

Acronyms

ACE

Angiotensin-converting enzyme

CHD

Congenital heart disease

PAH

Pulmonary arterial hypertension

PAH-CHD

Pulmonary arterial hypertension related to congenital heart disease

SNPs

Single nucleotide polymorphisms

TCPC

Total cavopulmonary connection

References

  1. 1.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRefGoogle Scholar
  2. 2.
    Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol. 2008;52(23):e143–263.CrossRefGoogle Scholar
  3. 3.
    Baumgartner H, Bonhoeffer P, De Groot NMS, de Haan F, Deanfield JE, Galie N, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31(23):2915–57.CrossRefGoogle Scholar
  4. 4.
    van der BT, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, et al. Effect of valsartan on systemic right ventricular function a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013;127(3):322–30.CrossRefGoogle Scholar
  5. 5.
    Robinson B, Heise CT, Moore JW, Anella J, Sokoloski M, Eshaghpour E. Afterload reduction therapy in patients following intraatrial baffle operation for transposition of the great arteries. Pediatr Cardiol. 2002;23(6):618–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Therrien J, Provost Y, Harrison J, Connelly M, Kaemmerer H, Webb GD. Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study. Int J Cardiol. 2008;129(2):187–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Dimopoulos K. Trials and tribulations in adult congenital heart disease. Int J Cardiol. 2008;129(2):160–2.CrossRefPubMedGoogle Scholar
  8. 8.
    Gurvitz M, Burns KM, Brindis R, Broberg CS, Daniels CJ, Fuller SMPN, et al. Emerging research directions in adult congenital heart disease: a report from a National Heart, Lung, and Blood Institute/Adult Congenital Heart Association Working Group. J Am Coll Cardiol. 2016;67(16):1956–64.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Dimopoulos K, Alonso-Gonzalez R, D’Alto M. Heart failure, exercise intolerance, and physical training. In: Diagnosis and management of adult congenital heart disease [Internet]. 3rd ed. 2017 [cited 2017 Mar 27]. https://www.elsevier.com/books/diagnosis-and-management-of-adult-congenital-heart-disease/unknown/978-0-7020-6929-1.
  10. 10.
    Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, et al. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2016;133(8):770–801.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Tutarel O, Kempny A, Alonso-Gonzalez R, Jabbour R, Li W, Uebing A, et al. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J. 2014;35(11):725–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Gatzoulis MA, Clark AL, Cullen S, Newman CG, Redington AN. Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot. Restrictive physiology predicts superior exercise performance. Circulation. 1995;91(6):1775–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Diller G-P, Dimopoulos K, Okonko D, Uebing A, Broberg CS, Babu-Narayan S, et al. Heart rate response during exercise predicts survival in adults with congenital heart disease. J Am Coll Cardiol. 2006;48(6):1250–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Alonso-Gonzalez R, Borgia F, Diller G-P, Inuzuka R, Kempny A, Martinez-Naharro A, et al. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation. 2013;127(8):882–90.CrossRefPubMedGoogle Scholar
  15. 15.
    Dimopoulos K, Diller G-P, Giannakoulas G, Petraco R, Chamaidi A, Karaoli E, et al. Anemia in adults with congenital heart disease relates to adverse outcome. J Am Coll Cardiol. 2009;54(22):2093–100.CrossRefPubMedGoogle Scholar
  16. 16.
    Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. 2014;35(11):691–700.CrossRefPubMedGoogle Scholar
  17. 17.
    Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD, Lu M, et al. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med. 2010;362(21):1980–92.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kempny A, Hjortshøj CS, Gu H, Li W, Opotowsky AR, Landzberg MJ, et al. Predictors of death in contemporary adult patients with Eisenmenger syndrome: a multicenter study. Circulation. 2017;135(15):1432–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008;117(3):363–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Giannakoulas G, Dimopoulos K, Bolger AP, Tay EL, Inuzuka R, Bedard E, et al. Usefulness of natriuretic peptide levels to predict mortality in adults with congenital heart disease. Am J Cardiol. 2010;105(6):869–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Sharma R, Bolger AP, Li W, Davlouros PA, Volk H-D, Poole-Wilson PA, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol. 2003;92(2):188–93.CrossRefPubMedGoogle Scholar
  22. 22.
    Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002;106(1):92–9.CrossRefPubMedGoogle Scholar
  23. 23.
    McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    NOTE registry|ISACHD [Internet]. [cited 2017 Dec 3]. http://www.isachd.org/content/note-registry.
  26. 26.
    The British Association for Cardiovascular Prevention and Rehabilitation. The BACPR standards and core components for cardiovascular disease prevention and rehabilitation [Internet]. 2017 [cited 2016 Sep 23]. http://www.bacpr.com/pages/page_box_contents.asp?pageid=791.
  27. 27.
    Dua JS, Cooper AR, Fox KR, Graham Stuart A. Exercise training in adults with congenital heart disease: feasibility and benefits. Int J Cardiol. 2010;138(2):196–205.CrossRefPubMedGoogle Scholar
  28. 28.
    Duppen N, Kapusta L, de Rijke YB, Snoeren M, Kuipers IM, Koopman LP, et al. The effect of exercise training on cardiac remodelling in children and young adults with corrected tetralogy of Fallot or Fontan circulation: a randomized controlled trial. Int J Cardiol. 2015;179:97–104.CrossRefPubMedGoogle Scholar
  29. 29.
    Becker-Grünig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, et al. Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;168(1):375–81.CrossRefPubMedGoogle Scholar
  30. 30.
    van der Bom T, Winter MM, Knaake JL, Cervi E, de Vries LSC, Balducci A, et al. Long-term benefits of exercise training in patients with a systemic right ventricle. Int J Cardiol. 2015;179:105–11.CrossRefPubMedGoogle Scholar
  31. 31.
    Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–81.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Lewis M, Rosenbaum M. The miracle baby grows up: hypoplastic left heart syndrome in the adult. Curr Cardiol Rep. 2017;19(8):74.CrossRefPubMedGoogle Scholar
  33. 33.
    Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54.CrossRefGoogle Scholar
  34. 34.
    Galie N, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, et al. Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomised controlled MAESTRO study. Eur Heart J [Internet]. 2017 Aug 1 [cited 2017 Dec 3];38(suppl_1). https://academic.oup.com/eurheartj/article/38/suppl_1/ehx493.P5462/4086822.
  35. 35.
    Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, et al. Inhaled nitric oxide as a preoperative test (INOP test I): the INOP test study group. Circulation. 2002;106(12 Suppl 1):I76–81.PubMedGoogle Scholar
  36. 36.
    Frescura C, Thiene G, Giulia Gagliardi M, Mazzucco A, Pellegrino PA, Daliento L, et al. Is lung biopsy useful for surgical decision making in congenital heart disease? Eur J Cardiothorac Surg. 1991;5(3):118–22. discussion 122–3CrossRefPubMedGoogle Scholar
  37. 37.
    Wagenvoort CA. Morphological substrate for the reversibility and irreversibility of pulmonary hypertension. Eur Heart J. 1988;9(Suppl J):7–12.CrossRefPubMedGoogle Scholar
  38. 38.
    Novick WM, Sandoval N, Lazorhysynets VV, Castillo V, Baskevitch A, Mo X, et al. Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance. Ann Thorac Surg. 2005;79(1):21–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol. 2008;129(2):163–71.CrossRefPubMedGoogle Scholar
  40. 40.
    Perera AH, Rudarakanchana N, Hamady M, Kashef E, Mireskandari M, Uebing A, et al. New-generation stent grafts for endovascular management of thoracic pseudoaneurysms after aortic coarctation repair. J Vasc Surg. 2014;60(2):330–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Benza R, Correa-jaque P, Franco V, Doyle M, White JA, Ginn G, et al. Abstract 19282: safety and utility of the CardioMEMs device in pulmonary arterial hypertension. Circulation. 2016;134(Suppl 1):A19282.Google Scholar
  42. 42.
    Janoušek J, Gebauer RA, Abdul-Khaliq H, Turner M, Kornyei L, Grollmuß O, et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart. 2009;95(14):1165–71.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Janousek J, Tomek V, Chaloupecký VA, Reich O, Gebauer RA, Kautzner J, et al. Cardiac resynchronization therapy: a novel adjunct to the treatment and prevention of systemic right ventricular failure. J Am Coll Cardiol. 2004;44(9):1927–31.CrossRefPubMedGoogle Scholar
  44. 44.
    Authors/Task Force Members, Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867.CrossRefGoogle Scholar
  45. 45.
    Lutembacher R. De la sténose mitrale avec communication interauriculaire. Arch Mal Coeur. 1916;9:237–60.Google Scholar
  46. 46.
    Hasenfuß G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet Lond Engl. 2016;387(10025):1298–304.CrossRefGoogle Scholar
  47. 47.
    Kaye DM, Hasenfuß G, Neuzil P, Post MC, Doughty R, Trochu J-N, et al. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(12):pii: e003662.CrossRefGoogle Scholar
  48. 48.
    Trigo MD, Bergeron S, Bernier M, Amat-Santos IJ, Puri R, Campelo-Parada F, et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet. 2016;387(10025):1290–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail. 2015;3(6):487–96.CrossRefPubMedGoogle Scholar
  50. 50.
    Barostim therapy for heart failure—full text view. ClinicalTrials.gov [Internet]. [cited 2017 Dec 3]. https://clinicaltrials.gov/ct2/show/NCT02627196.
  51. 51.
    Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet Lond Engl. 2016;388(10048):974–82.CrossRefGoogle Scholar
  52. 52.
    Jagielski D, Ponikowski P, Augostini R, Kolodziej A, Khayat R, Abraham WT. Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months’ experience with the remedē® System. Eur J Heart Fail. 2016;18(11):1386–93.CrossRefPubMedGoogle Scholar
  53. 53.
    Weber B, Dijkman PE, Scherman J, Sanders B, Emmert MY, Grünenfelder J, et al. Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model. Biomaterials. 2013;34(30):7269–80.CrossRefPubMedGoogle Scholar
  54. 54.
    Duan B, Kapetanovic E, Hockaday LA, Butcher JT. Three-dimensional printed trileaflet valve conduits using biological hydrogels and human valve interstitial cells. Acta Biomater. 2014;10(5):1836–46.CrossRefGoogle Scholar
  55. 55.
    Truskey GA. Advancing cardiovascular tissue engineering. F1000Research [Internet]. 2016 May 31 [cited 2017 Nov 27];5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890312/.
  56. 56.
    Ross HJ, Law Y, Book WM, Broberg CS, Burchill L, Cecchin F, et al. Transplantation and mechanical circulatory support in congenital heart disease a scientific statement from the American Heart Association. Circulation. 2016;133(8):802–20.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of congenital heart disease: the glass half empty. Circ Res. 2013;112(4):707–20.CrossRefPubMedGoogle Scholar
  58. 58.
    Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008 Jan;29(2):270–6.CrossRefGoogle Scholar
  59. 59.
    Yang J, Xu W-W, Hu S-J. Heart failure: advanced development in genetics and epigenetics. Biomed Res Int. 2015;2015:352734.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Preuss C, Andelfinger G. Genetics of heart failure in congenital heart disease. Can J Cardiol. 2013;29(7):803–10.CrossRefPubMedGoogle Scholar
  61. 61.
    Postma AV, van Engelen K, van de Meerakker J, Rahman T, Probst S, Baars MJH, et al. Mutations in the sarcomere gene MYH7 in Ebstein anomaly. Circ Cardiovasc Genet. 2011 Feb;4(1):43–50.CrossRefPubMedGoogle Scholar
  62. 62.
    Lopes LR, Elliott PM. Genetics of heart failure. Biochim Biophys Acta. 2013;1832(12):2451–61.CrossRefPubMedGoogle Scholar
  63. 63.
    Kirwan JR, de Wit M, Frank L, Haywood KL, Salek S, Brace-McDonnell S, et al. Emerging guidelines for patient engagement in research. Value Health. 2017;20(3):481–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ. 2015;350:g7818.CrossRefPubMedGoogle Scholar
  65. 65.
    Moons P, Kovacs AH, Luyckx K, Thomet C, Budts W, Enomoto J, et al. Patient-reported outcomes in adults with congenital heart disease: inter-country variation, standard of living and healthcare system factors. Int J Cardiol. 2017;251:34–41.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Konstantinos Dimopoulos
    • 1
  • Alessia David
    • 2
  1. 1.Adult Congenital Heart Centre and National Centre for Pulmonary HypertensionRoyal Brompton Hospital and Imperial College LondonLondonUK
  2. 2.Centre for Bioinformatics and System BiologyImperial College LondonLondonUK

Personalised recommendations